Based on 2 reference(s) in Google Scholar 10 10 2

Axon 2633

CAS [1801747-42-1]

MF C16H19Cl2N5
MW 352.26

  • Purity: 99%
  • Soluble in DMSO



Highly potent, selective and orally bioavailable SHP2 inhibitor (IC50 value 0.071 μM) that stabilizes SHP2 in an auto-inhibited conformation. SHP099 potently inhibits ERK phosphorylation and the growth of cancer cell lines that have alterations in RTKs or other tyrosine kinases such as the Janus kinases JAK1 and JAK2. SHP099 showed no detectable activity against a panel of 21 phosphatases and 66 kinases (including the closest homologue SHP1), and only had modest activity against 5HT3 when profiled against a preclinical safety pharmacology panel representing 49 common adverse drug reaction targets.

KEYWORDS: SHP099 | supplier | SHP2 inhibitor | SHP-099 | SHP 099 | CAS [1801747-42-1] | [1801747-11-4] | Tyrosine Phosphatase | PTP | PTPN11 | PTP-2C | programmed cell death pathway | PD-1/PD-L1 | Noonan | Leopard | RAS-ERK signaling

Size Unit Price Stock
5 mg €80.00 In Stock
25 mg €240.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €120.00 In Stock
2 x 25 mg €360.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...